Introduction {#Sec1}
============

Systemic low-grade inflammation is thought to play a central role in the development of insulin resistance, leading to type 2 diabetes and cardiovascular diseases \[[@CR1]\]. Such inflammation is defined by a two- to threefold increase in circulating cytokines such as TNF-α, IL-6 and IL-18. Low-grade inflammation is typically associated with increased levels of NEFA, hyperinsulinaemia, visceral fat accumulation and low adiponectin levels \[[@CR1]\].

Much attention has been focused on persistent low-grade inflammation in obesity. In the obese state, macrophages are recruited to the adipose tissue. The macrophages subsequently produce cytokines, causing a low-grade inflammatory response \[[@CR1]\]. However, the mechanisms that lead to this proinflammatory state are still being investigated.

In obesity, both visceral and subcutaneous fat are sources of systemic low-grade inflammation \[[@CR2]\]. Indeed, the distribution of adipose tissue, rather than the total amount of fat, seem to be associated with systemic low-grade inflammation \[[@CR3]--[@CR5]\].

This is illustrated by the lipodystrophy syndrome, where patients lose subcutaneous fat in the limbs and accumulate visceral fat, both of which processes are associated with systemic low-grade inflammation and accompanied by insulin resistance, increased lipolysis and consequently increased levels of NEFA \[[@CR6]\]. The most common form of lipodystrophy is the acquired lipodystrophy seen in HIV-infected patients on highly active antiretroviral therapy (HAART) \[[@CR7]\].

It is well established that NEFAs promote insulin resistance with compensatory hyperinsulinaemia \[[@CR8]\], but NEFAs have also been suggested to be the underlying cause of systemic low-grade inflammation \[[@CR8]\]. In support of this, NEFAs are able to engage toll-like receptor (TLR)s, activate nuclear factor κB (NF-κB) and induce proinflammatory production of TNF-α and IL-6 \[[@CR9]\] at least in vitro. Despite the tight association between increased NEFA levels and systemic inflammation in humans, very few studies in humans have been conducted, and all except for one \[[@CR10]\] are based on an endotoxin experimental model \[[@CR11]--[@CR15]\]. Thus it still remains elusive as to whether NEFAs directly influence human cytokine levels in vivo.

While most systemic inflammatory molecules are released from immune cells, adiponectin is released primarily from adipocytes. Low levels of adiponectin are often associated with low-grade inflammation and increased levels of NEFA. Adiponectin has anti-inflammatory effects and decreases circulating NEFAs \[[@CR16]\]. Conversely, increased circulating NEFAs decrease circulating adiponectin \[[@CR17]\]. It remains unknown whether lowering of NEFA levels regulates adiponectin, as divergent results have been reported from studies using the anti-lipolytic drug acipimox, a nicotinic acid \[[@CR10], [@CR18]--[@CR20]\]. However, as adiponectin is produced primarily by adipocytes, it can be argued that adiponectin may not sense circulating NEFA levels. Thus, the relationship between adiponectin and circulating NEFA may in fact reflect the possibility that adiponectin and other adipokines are regulated by the anti-lipolytic effect as such. To explore this, we used acipimox and insulin, both of which affect lipolysis through different intracellular pathways. The anti-lipolytic effect of acipimox takes place after the inhibitory regulative G protein action of a G protein-coupled receptor (HM74b), occurring probably with no other effects on the cell and leading to reduced intracellular concentrations of cAMP \[[@CR21], [@CR22]\]. Insulin also reduces intracellular cAMP, but through a completely different mechanism, namely activation of phosphodiesterases \[[@CR22]\]. In addition, insulin exerts its effects via downstream signalling through phosphoinositide 3-kinase, activating, for example, mitogen-activated protein kinase. To better understand the effect on adipokine regulation of inhibiting intracellular lipolysis and lowering systemic NEFA, we explored the in vivo effects of acipimox and insulin on adiponectin and cytokine levels in patients with HIV-associated lipodystrophy. Acipimox and a two-stage euglycaemic--hyperinsulinaemic clamp were used as tools to induce anti-lipolysis, based on our hypothesis that inhibition of lipolysis would inhibit adipokine production and thereby decrease circulating cytokine and adiponectin levels.

Methods {#Sec2}
=======

Participants {#d30e433}
------------

We recruited nine non-diabetic HIV-positive men on stable HAART from the Outpatient Clinic of the Department of Infectious Disease (Rigshospitalet, Copenhagen, Denmark). A description of selection, anthropometry, HIV-immunology and components of HAART for all participants has been previously published \[[@CR23]\]. In brief, the patients were included on the basis of: (1) lipoatrophy (at least one moderate sign of lipoatrophy) \[fat loss\] in face, arms, buttocks or legs based on a physical examination; and (2) the presence of insulin resistance (fasting plasma insulin ≥104 pmol/l). If fasting plasma insulin was \<104 pmol/l, a standard 75 g OGTT was done and the participant included if insulin was \>521 pmol/l after 120 min. Patient characteristics appear in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristics of the study patients*N*9Age (years)52.3 ± 8.7HIV infection duration (years)16.3LogHIV RNA (copies/ml)1.90 ± 1.65CD4+ cell counts (cells/μl)732 ± 354Body weight (kg)81.9 ± 9.6BMI (kg/m^2^)25.0 ± 2.4Body fat (%)19.9 ± 6.6Fat mass (kg)16.8 ± 7.2Lean body mass (kg)62.5 ± 38.1Truncal fat mass (kg)10.4 ± 4.8Truncal fat mass (%)60.7 ± 11.13Limb fat mass (kg)5.5 ± 2.85Limb fat mass (%)33.4 ± 10.11Trunk:limb ratio2.00 ± 1.08Fasting glucose (mmol/l)5.5 ± 0.69Fasting insulin (pmol/l)86 ± 54Fasting triacylglycerol (mmo/l)3.07 ± 2.22Fasting total cholesterol (mmol/l)6.1 ± 1.4Fasting HDL-cholesterol (mmol/l)1.4 ± 1.05Fasting LDL-cholesterol (mmol/l)3.73 ± 2.22Fasting NEFAs (μmol/l)412 ± 183.9Fasting TNF-α (pg/ml)1.08 (0.95--3.22)Fasting IL-18 (pg/ml)304 (237--382)Fasting IL-6 (pg/ml)2.01 (1.68--3.22)Fasting adiponectin (μg/ml)1.98 (1.37--3.03)Data are mean ± SD; for cytokines the data are median and 25% and 75% quartiles

Informed consent was obtained from all patients according to the requirements of the local Ethics Committee and the Helsinki Declaration.

Design {#d30e650}
------

The study was a randomised double-blinded crossover study. Each participant was studied twice at an interval of at least 2 weeks, receiving acipimox on the one occasion and placebo on the other. The HAART medication was taken 3.5 to 4.5 h before commencing the clamp, with no change to the HAART combination during the study. This enabled us to eliminate the effect of HAART on the cytokine response. Acipimox was administered in doses of 250 mg at 07:00 hours and 24:00 hours (midnight) on the day/night before, and at 07:00 and 09:00 hours on the day of the study. The timing of acipimox treatment and the euglycaemic clamp in relation to fasting was chosen according to previous studies \[[@CR24], [@CR25]\]. The study protocol has been described elsewhere \[[@CR23]\]. In brief, on each study day, participants reported to the laboratory at 07:00 hours after an overnight fast. Peripheral catheters were inserted into an antecubital vein for blood sampling, in the contralateral antecubital vein for infusion of fluids and in a dorsal hand vein for blood sampling. The hand was wrapped in a heating blanket to obtain arterialised blood samples. After catheterisation, venous blood samples were obtained at 0, 30, 60, 90, 120 and 150 min for measurement of plasma NEFA, and at 0, 90 and 150 min (basal stage) for measurement of cytokine levels. At 2.5 h later, a two-stage euglycaemic--hyperinsulinaemic clamp was initiated and continued for 6 h, according to a previously published protocol \[[@CR26]\] with some modifications. Insulin (100 IU/ml; Actrapid; Novo Nordisk, Bagsvaerd, Denmark) was infused for 2 h (stage 1) at a rate of 20 mU m^−2^ min^−1^ (initiated with a two-step priming dose of 80 mU m^−2^ min^−1^ for 5 min, followed by 40 mU m^−2^ min^−1^ for 5 min), and for the following 4 h (stage 2) at a rate of 50 mU m^−2^ min^−1^ (initiated with a two-step priming dose of 200 mU BSA m^−2^ min^−1^ for 5 min, followed by 100 mU m^−2^ min^−1^ for 5 min). The blood glucose concentration was kept at 5.5 mmol/l by a variable-rate infusion of 20% glucose. To maintain euglycaemia, arterialised blood glucose was measured every 5 min in the first hour of each clamp stage and every 10 min during the rest of the clamp, with samples being immediately analysed (EML 105; Radiometer, Copenhagen, Denmark). During the euglycaemic--hyperinsulinaemic clamp, venous blood samples were obtained for measurement of NEFA and cytokine levels at 180, 210, 240 and 270 min during stage 1, and at 300, 330, 390, 450 and 510 min during stage 2. As one participant did not complete the clamp study for technical reasons, results during the clamp represent data from eight participants only.

Laboratory analyses {#d30e705}
-------------------

All blood samples were drawn into tubes containing EDTA and centrifuged (3,000  *g*). Plasma was stored at −80°C. Plasma concentrations of IL-18, TNF-α, IL-6 and insulin were determined by ELISA (TNF-α and IL-6: Quantikine High Sensitivity, R&D Systems, Minneapolis, MN, USA; insulin: DakoCytomation, Ely, UK; IL-18: Medical and Biological Laboratories, Nagoya, Japan). Plasma concentrations of adiponectin were determined by a human adiponectin RIA kit (Linco Research, St Charles, MO, USA). Plasma concentrations of NEFA were determined using an automatic analyser (Cobas fara; Roche, Basel, Switzerland; and NEFA C; Wako Chemicals, Neuss, Germany). The detection limits were 12.5 pg/ml for IL-18, 0.094 pg/ml for TNF-α, 0.18 pg/ml for IL-6, 0.51 pmol/l for insulin and 1 ng/ml for adiponectin. All determinations were run as duplicates and mean values calculated.

Total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l), triacylglycerol (mmol/l) and glucose (mmol/l) measurements on the day of inclusion were determined using standard laboratory procedures. CD4^+^ cell counts were calculated by flow cytometry and HIV-RNA copies were measured with an Amplicor HIV Monitor (Roche Molecular Systems, Branchburg, NJ, USA) (lower limit of detection: 20 copies/ml).

Statistical analysis {#d30e718}
--------------------

Values of cytokines, NEFA and insulin were natural log-transformed to achieve homogeneity of variance and an approximate normal distribution. Statistical analyses of the plasma measurements were carried out using a multivariate linear mixed-effects regression model \[[@CR27]\]. The effect of treatment was estimated using a binary variable (acipimox or placebo). The effect of insulin infusion was estimated using a categorical variable, i.e. none, low (20 mU m^−2^ min^−1^) or high (50 mU m^−2^ min^−1^) infusion level, with a model that allowed for an interaction term between treatment and insulin infusion when needed. During the insulin infusion, time in minutes was entered as a continuous variable in the analysis of plasma variables, allowing for different effects during low and high insulin infusion, respectively. Thus, the categorical effect variable of insulin models the effect of a different insulin level in plasma, leading to a constant change in the level of the response variable, whereas the time effect during insulin infusion models the cumulative effect over time of a higher insulin level, leading to a rate change in the response variable. A random participant-specific component was introduced at the baseline level and allowed adjustment for inter-individual variations. This introduces a positive correlation between measurements from the same participant, while measurements from different participants are independent. The study protocol was designed to measure plasma TNF-α, IL-6, IL-18 and adiponectin concentrations from the same individual at several time-points. The statistical models take into account the fact that observations come from the same person \[[@CR27]\]. In this way, the total variation is split into the within-participant and between-participant variations, which are known to appear in cytokine response under various stimuli \[[@CR28]\], thereby improving the estimation of variables in the study population. Likelihood ratio tests were applied to assess statistical significance. The final model was found by backward stepwise regression. Thus, in the final models, only the terms that were statistically significant were retained. Statistical significance was defined as *p* \< 0.05. The fit of the general linear model was evaluated by testing the residuals for normality and by inspection of the residual plots. For the analysis, the procedure lme in R (version 2.1) was used \[[@CR29]\]. Results are presented as estimates (95% CI) if not otherwise stated.

Results {#Sec3}
=======

Baseline characteristics {#d30e754}
------------------------

The participants' clinical characteristics are in Table [1](#Tab1){ref-type="table"}. All participants had lipodystrophy as indicated by a decreased percentage of limb fat (limb fat percentage in healthy men 45.3%) \[[@CR30]\] and an increased percentage of trunk fat (trunk fat percentage in healthy men 50.9%) \[[@CR30]\]. The participants had elevated plasma triacylglycerol (value in men with hypertriacylglycerolaemia \>1.7 mmol/l, according to WHO \[[@CR31]\]) and NEFA concentrations (value in healthy men 292 ± 58 μmol/l \[mean ± SEM\]) \[[@CR32]\]. As an indication of low-grade inflammation, the participants had elevated plasma TNF-α and IL-18 levels, and decreased plasma adiponectin levels (Table [1](#Tab1){ref-type="table"}) compared with cytokine levels in healthy controls obtained in other studies performed in our laboratory (values \[median and 25% and 75% quartiles\] in healthy men: TNF-α 0.32 \[0.08--0.83\] pg/ml \[[@CR30]\]; IL-18 111.6 \[62.3--171.3\] pg/ml \[[@CR33]\]; adiponectin 9.10 \[4.32--12.05\] μg/ml \[[@CR30]\]; IL-6 1.99 \[1.45--3.8\] pg/ml \[[@CR30]\]).

All patients were receiving HAART and at least one nucleoside analogue; seven were receiving at least one protease inhibitor and five a non-nucleoside analogue. All patients except one had suppressed HIV-RNA (HIV-RNA \<18 copies/ml).

Insulin and glucose concentrations {#d30e792}
----------------------------------

Insulin increased in stage 1 of the euglycaemic--hyperinsulinaemic clamp and increased further in stage 2 of the clamp, while all patients were euglycaemic. Basal plasma glucose and insulin concentrations did not differ between the placebo and acipimox trials \[[@CR23]\].

The effect of insulin and acipimox on NEFA concentrations {#d30e800}
---------------------------------------------------------

Low doses of insulin reduced plasma NEFA concentrations during stage 1, with no further reduction during high doses of insulin in stage 2 (basal NEFA 431 μmol/l, *p* \< 0.0001 for main treatment effect; NEFA, end of stage 1 232 μmol/l, *p* = 0.035).

Acipimox reduced basal plasma NEFA concentrations from 431 μmol/l to 209 μmol/l. Acipimox and a low dose of insulin infusion decreased plasma NEFA further to 167 μmol/l during stage 1. This reduction was more pronounced than with insulin alone (placebo) (*p* = 0.035 for interaction between insulin and treatment). Acipimox did not further reduce plasma NEFA during stage 2 (*p* = 0.27).

The anti-lipolytic effect on adiponectin and cytokines {#d30e819}
------------------------------------------------------

In Fig. [1](#Fig1){ref-type="fig"}, geometric means for the plasma concentrations of adiponectin (Fig. [1a](#Fig1){ref-type="fig"}), IL-18 (Fig. [1b](#Fig1){ref-type="fig"}), IL-6 (Fig. [1c](#Fig1){ref-type="fig"}) and TNF-α (Fig. [1d](#Fig1){ref-type="fig"}) are shown in the basal state, and at stages 1 and 2. In Fig. [2](#Fig2){ref-type="fig"}, the predicted levels of plasma adiponectin (Fig. [2a](#Fig2){ref-type="fig"}), plasma IL-18 (Fig. [2b](#Fig2){ref-type="fig"}), plasma IL-6 (Fig. [2c](#Fig2){ref-type="fig"}) and plasma TNF-α (Fig. [2d](#Fig2){ref-type="fig"}) appear as in the final statistical models, i.e. a mixed-effects model. The full model for all four cytokines has four main effects: treatment, insulin, time during stage 1 and time during stage 2. It has three interaction terms: treatment with insulin, time during stage 1 and time during stage 2, respectively. The final models were reduced to only retain terms that were significant at a 5% confidence level.Fig. 1(**a**) Geometric means ± SEM for plasma adiponectin, (**b**) plasma IL-18, (**c**) plasma IL-6 and (**d**) plasma TNF-α levels during the basal stage, low-dose insulin infusion (stage 1) and high-dose insulin infusion (stage 2) after overnight treatment with placebo (dashed lines) and acipimox (solid lines) in nine HIV-infected patients with lipodystrophy. The full statistical model for all four cytokines has four main effects: treatment, insulin, time during stage 1 and time during stage 2. It has three interaction terms: treatment with insulin, time during stage 1 and time during stage 2. The final models were reduced to only retain those terms significant at a 5% confidence level. The statistical results appear as: (1) the effect of acipimox or placebo (treatment, main effect); (2) low or high-dose insulin infusion (insulin, main effect); and (3) time during the different stages of the clamp (time effect); and they allow (4) for an interaction between treatment, insulin and time. The main effect of treatment was only significant for adiponectin (*p* = 0.0001) (**a**) and IL-18 (*p* \< 0.0001) (**b**), and was thus removed from the final models of IL-6 (**c**) and TNF-α (**d**). Likewise, the main effect of insulin was only significant for adiponectin (*p* \< 0.0001) (**a**) and IL-6 (*p* \< 0.0001) (**c**), and was thus removed from the final models of IL-18 (**b**) and TNF-α (**d**). Time was only significant during stage 1 for TNF-α (*p* = 0.024) (**d**), and during stage 2 for IL-18 (*p* = 0.046) (**b**) and IL-6 (*p* = 0.0001) (**c**). The time effects were removed in all other cases. Only one interaction term was retained, namely the interaction between treatment and time during stage 2 for IL-18 (*p* = 0.023) (**b**). In total, nine main effects and 11 interaction terms were removed from the final modelsFig. 2The predicted levels from the final statistical model of (**a**) plasma adiponectin, (**b**) plasma IL-18, (**c**) plasma IL-6 and (**d**) plasma TNF-α during the basal stage, low-dose insulin infusion (stage 1) and high-dose insulin infusion (stage 2) after overnight treatment with placebo (blue dashed lines) and acipimox (blue solid lines) in nine HIV-infected patients with lipodystrophy. For IL-6 and TNF-α the solid lines are predicted values irrespective of treatment status, as no treatment effect was detected. Lines with slopes different from zero indicate a statistically significant cumulative effect of insulin over time beyond the instantaneous effect of a change in insulin infusion. A statistically significant effect of a changed insulin level is shown by discontinuous lines. Note that only one interaction (insulin × time × treatment) term was retained, namely for IL-18 during high insulin infusion, where the effect of insulin depends on treatment status. Grey symbols indicate observed values (squares during placebo, triangles during acipimox treatment), and grey lines connect measurements from the same participant and day during placebo (dashed grey lines) and during treatment (solid grey lines). The main effect of treatment was only significant for adiponectin (*p* = 0.0001) (**a**) and IL-18 (*p* \< 0.0001) (**b**), and was thus removed from the final models of IL-6 (**c**) and TNF-α (**d**). Similarly, the main effect of insulin was only significant for adiponectin (*p* \< 0.0001) (**a**) and IL-6 (*p* \< 0.0001) (**c**), and was thus removed from the final models of IL-18 (**b**) and TNF-α (**d**). Time was only significant during stage 1 for TNF-α (*p* = 0.024) (**d**), and during stage 2 for IL-18 (*p* = 0.046) (**b**) and IL-6 (*p* = 0.0001) (**c**). The time effects were removed in all other cases. Only one interaction term was retained, namely the interaction between treatment and time during stage 2 for IL-18 (*p* = 0.023) (**b**). In total, nine main effects and 11 interaction terms were removed from the final models

Plasma adiponectin decreased when lipolysis was inhibited by acipimox and insulin, and consequently plasma NEFA levels were low (Figs [1a](#Fig1){ref-type="fig"} and [2a](#Fig2){ref-type="fig"}). Acipimox reduced basal plasma adiponectin levels from 2.23 μg/ml (1.41--3.53) to 1.91 μg/ml (1.12--3.25). During stage 1 of the clamp, plasma adiponectin decreased to 1.64 μg/ml (0.87--3.10), decreasing further in stage 2 to 1.48 μg/ml (0.79--2.79). During each stage, the reduction in plasma adiponectin was more pronounced with acipimox than with insulin alone (placebo) (*p* = 0.0001 for main treatment effect).

Insulin reduced basal plasma adiponectin from 2.23 (1.41--3.53) to 1.92 (1.1--3.37) in stage 1 and further to 1.74 (1.0--3.1) in stage 2 (*p* \< 0.0001 for, main insulin effect).

Plasma IL-18 decreased when lipolysis was inhibited by acipimox and insulin, and consequently plasma NEFA levels were low (Figs [1b](#Fig1){ref-type="fig"} and [2b](#Fig2){ref-type="fig"}). Acipimox reduced basal plasma IL-18 from 310 pg/ml to 284 pg/ml, with no further reduction of IL-18 occurring (*p* \< 0.0001 for main treatment effect). Insulin reduced basal plasma IL-18 from 310 pg/ml (248--389) to 285 pg/ml (193--423) at the end of stage 2 (*p* = 0.023 for interaction between treatment and time during stage 2).

Neither plasma TNF-α, nor plasma IL-6 concentrations responded to the inhibition of lipolysis by acipimox or insulin. In contrast, during stage 1, insulin actually increased plasma IL-6 from 2.97 pg/m to 3.49 pg/ml (2.31--5.27), with a further increase during stage 2 to 5.41 pg/ml (2.79--10.51) (*p* \< 0.0001 for insulin, main effect; *p* = 0.0001 for time during stage 2) (Figs [1c](#Fig1){ref-type="fig"} and [2c](#Fig2){ref-type="fig"}). Similarly, during stage 1, insulin increased basal plasma TNF-α from 1.26 pg/ml (0.98--1.62) to 1.31 pg/ml (0.98--1.76) (*p* = 0.024 for time during stage 1) with no further increase during stage 2 (Figs [1d](#Fig1){ref-type="fig"} and [2d](#Fig2){ref-type="fig"}).

Discussion {#Sec4}
==========

In this acute intervention study, lipolysis was inhibited by two completely different methods, acipimox and insulin, in order to investigate the anti-lipolytic effect on systemic levels of adiponectin and cytokines in lipodystrophy patients. The major finding was that acute anti-lipolysis, reflected by a reduction in NEFA, is sufficient to lower plasma adiponectin and plasma IL-18. This suggests that either intracellular inhibition of lipolysis or reduction of NEFA as such is capable of regulating production and hence circulating levels of adiponectin and IL-18. Anti-lipolysis did not influence TNF-α and IL-6 plasma levels; however, hyperinsulinaemia increased circulating IL-6 and TNF-α levels, suggesting that insulin, and not NEFA regulates IL-6 and TNF-α.

The anti-lipolytic effect on adiponectin {#d30e1085}
----------------------------------------

Previous studies have found that chronically and acutely elevated NEFA levels suppress adiponectin secretion in vivo \[[@CR17], [@CR34]\]. In agreement with our hypothesis, we found that intracellular inhibition of lipolysis reduced plasma adiponectin, probably reflecting reduced intracellular production. This result was evident with both forms of lipolysis inhibition, i.e. insulin and acipimox. In agreement with our findings, previous studies using acipimox found a reduction in circulating adiponectin in healthy men with moderate overweight. However, others found \[[@CR18]\] no effect in healthy lean participants or in participants with a family history of type 2 diabetes \[[@CR10], [@CR20]\]. The discrepancy between study results may be explained by the duration of administration (chronically in the study by Bajaj et al \[7 days\] \[[@CR10]\] vs acutely in a study by Bernstein et al \[6 h\] \[[@CR18]\] and in the current study \[13 h\]) or by the study design (open label administration in Staiger et al \[[@CR20]\] vs randomised, placebo-controlled crossover design as in a previous \[[@CR18]\] and the present study).

Interestingly, a positive correlation between circulating adiponectin and rate of appearance of glycerol was recently found when correcting for fat mass \[[@CR17]\]. It was suggested that circulating adiponectin represents a marker of total adipose tissue lipolytic capacity, a hypothesis that is supported by our results.

We can only speculate on the mechanisms underlying the decrease of adiponectin resulting from inhibition of lipolysis and reduced systemic NEFA levels. Adiponectin gene transcription is stimulated by several factors involved in adipogenesis, e.g. peroxisome proliferator-activated receptor (PPAR)γ, forkhead box O1 (FOXO1), CCAAT/enhancer-binding protein (C/EBP) alpha, sirtuin 1 and sterol regulatory element-binding protein 1. It is suppressed by hypoxia, transcription repressors such as nuclear factor of activated T cells and CREB, and by inflammatory cytokines such as TNF-α, IL-6 and IL-18 \[[@CR16]\]. As TNF-α and IL-6 did not respond to inhibition of lipolysis, a pathway through TNF-α and IL-6 is unlikely.

NEFAs are directly involved in cellular signalling pathways and regulation of gene transcription, and it has recently been proposed that lipolysis is required to promote PPARγ-activated expression of lipogenic genes \[[@CR22]\]. When acipimox reduces NEFA, it may lead to reduced *PPARG* expression, and thereby reduced adiponectin gene expression and reduced circulating adiponectin as seen in our study. This is supported by a previous study, where elevating NEFA in healthy males increased adipose tissue *PPARG* mRNA levels \[[@CR35]\]. Other factors upregulating adiponectin gene transcription such as FOXO1 and sirtuin 1 are inhibited by NEFA in vitro and in mice \[[@CR36], [@CR37]\], and may therefore not explain our results, although levels in these former studies were not investigated in an acipimox trial.

Given that insulin and acipimox inhibit lipolysis and lower plasma NEFA levels, it has already been suggested that some effects on gene expression may be shared by nicotinic acid and insulin \[[@CR38]\].

As suggested previously, adiponectin may not sense circulating NEFA levels. It has recently been proposed that lipolytic products and intermediates participate in cellular signalling processes \[[@CR22]\]. The anti-lipolytic effect of acipimox and insulin takes place through different pathways, leading to reduced intracellular concentrations of cAMP. As insulin and acipimox decreased plasma adiponectin, our findings suggest that the secretion of adiponectin is regulated by anti-lipolytic effect as such.

The anti-lipolytic effect on IL-18 {#d30e1159}
----------------------------------

To our knowledge the anti-lipolytic effect on plasma IL-18 has not previously been examined in vivo. Plasma levels of IL-18 are increased in obesity \[[@CR39]\] and lipodystrophy \[[@CR33]\], and are associated with several components of the metabolic syndrome, including hypertriacylglycerolaemia \[[@CR40]\] and insulin resistance. However, while this suggests that IL-18 is involved in the pathogenesis of insulin resistance \[[@CR41]\], IL-18-deficent mice are obese, insulin-resistant and dyslipidaemic compared with wild-type mice \[[@CR42]\]. This highlights the complexity of IL-18 actions in metabolism.

Our findings revealed that acute anti-lipolysis, resulting in low levels of NEFA, led to reduced amounts of circulating IL-18 and that insulin during acipimox treatment had no additive effect. This suggests that NEFA or lipolytic products, and not insulin as such, regulate systemic IL-18 in vivo. IL-18 secretion is regulated through TLRs. It may therefore be speculated that the regulation of IL-18 by NEFA occurs through engaging TLRs and the induction of NF-κB \[[@CR9]\]. Another possibility is through activation of the NLP3 (NLR family pyrin domain-containing 3)-ASC (apoptosis-associated speck-like protein) inflammasome, as NEFAs have recently been found to induce activation of the NLP3-ASC inflammasome, causing IL-1 beta and IL-18 production \[[@CR43]\]. A previous study found suppression of circulating IL-18 during acute hyperinsulinaemia in healthy controls \[[@CR44]\], and is thus supported by our data. However, our study adds to the former one in as far as we suggest that the reduction in plasma IL-18 is due to insulin-mediated inhibition of lipolysis. Together, these data suggest that in individuals with insulin resistance, chronically elevated systemic IL-18 may be causally linked to increased plasma NEFA levels and not to hyperinsulinaemia.

In line with the above sentences on the regulation of adiponectin, the regulation of IL-18 may also be related to a drug effect, as the G protein-coupled receptor 109A (GPR109A) has recently been found to be expressed in immune cells.

The anti-lipolytic effect on TNF-α and IL-6 {#d30e1192}
-------------------------------------------

Several lines of evidence show a relationship between NEFA and inflammation \[[@CR45]\]. In addition, NEFAs have been shown to increase *TNFA* (also known as *TNF*) expression in adipose tissue \[[@CR35]\], as well as IL-6 and TNFα secretion in adipocytes \[[@CR45]\]. We were therefore surprised that anti-lipolysis and the resultant lowered levels of NEFA with acipimox treatment or insulin did not affect TNF-α and IL-6. Bajaj et al also failed to find an effect of 7 days of acipimox treatment on circulating cytokines \[[@CR10]\]. However, this was less surprising as only healthy participants without low-grade inflammation were studied. The discrepancy between our results and the NEFA-induced augmentation of *TNFA* gene expression in adipose tissue and TNF-α secretion in vitro suggests that NEFAs have local, but no direct systemic effects.

The effect of NEFAs on inflammation has been investigated especially in models where inflammation is induced experimentally by infusion of endotoxin, with additional NEFA infusion enhancing the systemic cytokine response in some \[[@CR11]--[@CR13]\], but not all studies \[[@CR14], [@CR15]\]. Some differences between these studies are the observed changes in insulin and glucose concentrations induced by infusion of intralipid. For example, when systemic insulin increases, an enhancement of systemic cytokines occurs \[[@CR11]--[@CR13]\], whereas if insulin concentrations are kept stable with a hyperinsulinaemic--euglycaemic clamp, no effect on the systemic cytokine response occurs \[[@CR14], [@CR15]\]. Thus, as demonstrated in our study, insulin level control is critically important \[[@CR46]\]. For instance, upon clamping insulin at levels comparable to those seen in insulin-resistant individuals, we found that insulin (low insulin infusion stage), but not NEFA provoked an acute increase in TNF-α and IL-6, which can be interpreted to mean that while insulin increases systemic IL-6 and TNF-α, plasma NEFAs alone are insufficient to increase IL-6 and TNF-α.

In vitro, acipimox directly reduced the secretion of TNF-α and IL-6 through the GPR109A receptor in human monocytes \[[@CR47]\], while in various in vivo animal models, nicotinic acid inhibited vascular inflammation independently of changes in plasma lipids \[[@CR48], [@CR49]\]. However, we found that acipimox had no effect on TNF-α and IL-6, and thus acipimox did not regulate those cytokines in our study. Few studies have examined the acute effect of nicotinic acid in humans, and all those that we are aware of investigated the effect after a challenge with endotoxin, inducing very high levels of cytokines \[[@CR38]\].

Study limitations {#d30e1263}
-----------------

Our study has several limitations. One is that it lacks a healthy control group to control for the effect of HAART and immune deficiency. However, the participants acted as their own controls by taking the same antiretroviral medication at 3.5 to 4.5 h before each clamp on each study day, thereby controlling for the effect of HAART. Furthermore, all patients except one had suppressed HIV-RNA. Our aim, moreover, was to assess the effect of NEFA on inflammatory responses in a patient group with low-grade inflammation rather than in a group of healthy individuals, which has been described elsewhere. Patients with lipodystrophy have increased visceral fat, decreased subcutaneous fat, low-grade inflammation, insulin resistance and excess NEFA. The changes are therefore very similar to those occurring in obesity \[[@CR50]\] due to excessive food intake and lack of exercise. Although our study had a small sample size, we found differences between the trials on inflammatory cytokines and adiponectin; it is therefore likely that our results suggest a robust physiological response.

Conclusions {#d30e1271}
-----------

Using two different tools to manipulate lipolysis, the present study provides evidence that acute inhibition of lipolysis reduces levels of adiponectin and IL-18 in patients with HIV-associated lipodystrophy.
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